NCT06473519View on ClinicalTrials.gov

A Study to Assess Safety, Tolerability and Immunogenicity of RSVpreF From Multidose Vials in Healthy Female Adults.

PHASE3CompletedINTERVENTIONAL
Enrollment

453

Participants

Timeline

Start Date

June 24, 2024

Primary Completion Date

September 20, 2024

Study Completion Date

September 20, 2024

Conditions
Respiratory Syncytial Virus (RSV)
Interventions
BIOLOGICAL

RSVpreF MDV

RSVpreF with 2-PE formulated in an MDV

BIOLOGICAL

RSVpreF SDV

RSVpreF without 2-PE formulated in an SDV

Trial Locations (6)

30281

Clinical Research Atlanta, Stockbridge

33143

Qps-Mra, Llc, South Miami

48034

Headlands Research - Detroit, Southfield

78229

Clinical Trials of Texas, LLC dba Flourish Research, San Antonio

83404

Clinical Research Prime, Idaho Falls

83440

Clinical Research Prime Rexburg, Rexburg

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY